You searched for Gout - Page 46 of 96

Abstract Number: 2099 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Hirotaka Matsuo¹, Ken Yamamoto², Hirofumi Nakaoka³, Akiyoshi Nakayama¹, Masayuki Sakiyama¹, Atsushi Takahashi^4,5, Takahiro Nakamura⁶, Yusuke Kawamura¹, Nobuyuki Hamajima⁷, Ituro Inoue⁸, Michiaki Kubo⁴, Kimiyoshi Ichida⁹, Hiroshi Ooyama¹⁰, Toru Shimizu¹¹ and Nariyoshi Shinomiya¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Research Center, National Cerebral and Cardiovascular Center, Suita, Japan, ⁶National Defense Medical College, Laboratory for Mathematics, Tokorozawa, Japan, ⁷Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁹Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ¹⁰Ryougoku East Gate Clinic, Tokyo, Japan, ¹¹Midorigaoka Hospital, Takatsuki, Japan
Background/Purpose: Gout, caused by hyperuricaemia, is a multifactorial disease. Recently, genome-wide association studies (GWASs) of gout have been reported; however, they included self-reported gout cases.…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…
Abstract Number: 2110 • 2015 ACR/ARHP Annual Meeting
Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout
Nicola Dalbeth¹, Kenneth G. Saag², William Palmer³, Hyon Choi³, Barbara Hunt⁴, Patricia MacDonald⁴, Ulrich Thienel⁴ and Lhanoo Gunawardhana⁴, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: No clinical trials had previously investigated the characteristics of joint damage in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…
Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Alexandra Steinberg¹, Harinder Chera¹, Yun-Jung Choi¹, Robert Martin¹, Charles McWherter¹, Yunbin Zhang², Pol Boudes¹ and on behalf of the Arhalofenate Anti-Flare Therapy Study Group, ¹Cymabay Therapeutics, Newark, CA, ²INC Research, Raleigh, NC
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁶, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…
Abstract Number: 2228 • 2015 ACR/ARHP Annual Meeting
Brief Educational Intervention Improves Gout Patients’ Understanding of Their Disease
Slavica Bobic¹, Mark Tratenberg¹, Julia Ash¹, Amy Wasserman² and Kirk Sperber¹, ¹Rheumatology, New York Medical College, Valhalla, NY, ²New York Medical College, Valhalla, NY
Background/Purpose: To assess gout patients’ baseline knowledge of their disease and to measure knowledge improvement after brief educational session. Methods: In this study, 13 patients…
Abstract Number: 2239 • 2015 ACR/ARHP Annual Meeting
Prevalence of Gout and Hyperuricemia and Association with Fat Mass and Fat Free Mass: Results from a Population-Based Study
Tiffany K. Gill¹, Kimberley Ting², Graeme R Tucker¹, E. Michael Shanahan^3,4 and Catherine Hill^5,6, ¹Medicine, The University of Adelaide, Adelaide, Australia, ²Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³Flinders University, Adelaide, Australia, ⁴Repat General Hospital, Flinders University, Adelaide, Australia, ⁵The Health Observatory, The University of Adelaide, Adelaide, Australia, ⁶Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia
Background/Purpose: Gout and hyperuricemia are major co-morbid health issues worldwide, with a known association with metabolic syndrome. Only one previous study based in Vietnam, has…
Abstract Number: 2241 • 2015 ACR/ARHP Annual Meeting
Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
Marsha Raebel¹, Liza Reifler¹, David Tabano¹, Kristin Goddard¹, Andrew Sterrett¹, T Craig Cheetham², Leslie Harrold³, Daniel Sapp⁴, Mark Schmidt⁴, Javier Nuevo⁵, Robert Morlock⁶ and Gregory Nichols⁴, ¹Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, ²Kaiser Permanente Southern California, Pasadena, CA, ³Dept of Medicine, UMass Medical School, Worcester, MA, ⁴Center for Health Research, Kaiser Permanente Northwest, Portland, OR, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain, ⁶Ardea Bioscience, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend lowering serum urate (sUA) to a target value in patients with gout to prevent crystal deposition/promote crystal…
Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Sylvie Perreault¹, Javier Nuevo², Scott Baumgartner³ and Robert Morlock⁴, ¹University of Montreal, Montreal, QC, Canada, ²AstraZeneca, Madrid, Spain, Madrid, Spain, ³Ardea Biosciences, Inc., San Diego, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, Jonathan Chapnick⁴ and Javier Nuevo⁵, ¹4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
Abstract Number: 2244 • 2015 ACR/ARHP Annual Meeting
Risk of Incident Atrial Fibrillation in Gout
Seoyoung C. Kim¹, Jun Liu² and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Atrial fibrillation (AF) is the most common arrhythmia associated with cardiovascular disease and mortality. There are increasing data supporting the role of inflammation in…
Abstract Number: 2341 • 2015 ACR/ARHP Annual Meeting
Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey
Jasvinder A. Singh¹, Nipam Shah², N. Lawrence Edwards³ and H. Ralph Schumacher Jr.⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL, ³University of Florida, Gainsville, FL, ⁴Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: The interplay of use of dietary supplement, diet modification and ULT adherence in gout management is not known. Therefore, we aimed to begin to…
Abstract Number: 2344 • 2015 ACR/ARHP Annual Meeting
A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Naomi Schlesinger¹, Thomas Bardin^2,3, Mark Bloch⁴, Karine Lheritier⁵, Uwe Machein⁵, Guido Junge⁵, Alexander So⁶ and Rieke Alten⁷, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Hopital Lariboisière, Paris, France, ³Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁷Charité Univ Medicine, Berlin, Germany
Background/Purpose: Although anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs and colchicine are the recommended treatment options for pain and inflammation management in patients (pts) with…
Abstract Number: 2345 • 2015 ACR/ARHP Annual Meeting
Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Prashanth Sunkureddi¹, Rüdiger Moericke², Edith Tóth³, Jacques P Brown⁴, Uwe Machein⁵, Karine Lheritier⁵, Guido Junge⁵ and Alan J Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ³Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ⁴Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients with gouty arthritis (GA) experience frequent flares with pain and inflammation. The limited available treatment options and typical comorbidities warrant effective alternative treatments1.…

Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout

A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout

Imaging and Safety Assessments Following Treatment with Febuxostat and Placebo for 2 Years in Subjects with Early Gout

A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function

Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout

Brief Educational Intervention Improves Gout Patients’ Understanding of Their Disease

Prevalence of Gout and Hyperuricemia and Association with Fat Mass and Fat Free Mass: Results from a Population-Based Study

Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States

Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease

Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

Risk of Incident Atrial Fibrillation in Gout

Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey

A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine

Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study

Simple Search Results